Johnson & Johnson is leveraging artificial intelligence to accelerate several core processes across its pharmaceuticals and medical devices units, reducing the time required to optimize drug leads by about half, the company’s chief information officer said.
Speaking at a Reuters Momentum AI event in New York, CIO Jim Swanson said that while AI cannot yet independently invent new products and carry them through to market approval, the technology is being used to screen the "potential universe" of chemical compounds and biologics to identify promising candidates for further development.
"Thats still a ways away, but we can optimize," Swanson said, adding that J&J has cut lead optimization time in half. The New Jersey-based firm has been concentrating its AI efforts on clearly defined processes, including AI-enabled products, drug development workflows and supply chain optimization.
Swanson emphasized the company-wide goal: "Were trying to cure cancer. We need every tool that we can leverage to be able to do that." He also highlighted AI applications in manufacturing, where models help determine the appropriate timing and temperature for solvent additions during production.
Another major use case cited by Swanson is regulatory document preparation. He said the conventional process for generating a clinical trial report, which could previously require 700 to 900 hours, has been cut from "700 hours to about 15 minutes" through the use of AI tools.
On workforce implications, Swanson said J&J views AI as expanding employee capabilities rather than replacing staff. The company currently employs around 4,000 information technology professionals. "A software engineer isnt getting replaced, now their role is expanding," he said, stressing a focus on skills development. "Our focus continues to be on skills. These are and skills, not or skills."
Context and implications
J&Js remarks outline a targeted AI strategy that centers on increasing efficiency in drug lead optimization, refining manufacturing controls, and shortening compliance-related paperwork. The company is not claiming that AI has reached the point of fully autonomous drug discovery, but is using the technology to narrow candidate sets and speed routine tasks.
What remains limited
Swanson made clear that AI has not replaced humans at the company and that the tools are intended to augment employee skills, reflecting an approach that pairs technology with workforce development.